tiprankstipranks
Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
LSE:0H9X

Fresenius Medical Care AG & Co. KGaA (0H9X) Share Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

0H9X Analyst Ratings

Hold
11Ratings
2 Buy
5 Hold
4 Sell
Based on 11 analysts giving stock ratings to
Fresenius
Medical Care AG & Co. KGaA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0H9X Stock 12 Month Forecast

Average Price Target

€38.33
▲(4.53% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is €38.33 with a high forecast of €50.00 and a low forecast of €26.00. The average price target represents a 4.53% change from the last price of €36.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"€25","38":"€38","51":"€51","31.5":"€31.5","44.5":"€44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€38.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,31.5,38,44.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.22,37.28,38.339999999999996,39.4,40.46,41.519999999999996,42.58,43.64,44.7,45.76,46.82,47.879999999999995,48.94,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.22,36.38230769230769,36.54461538461538,36.706923076923076,36.86923076923077,37.03153846153846,37.19384615384615,37.356153846153845,37.51846153846154,37.68076923076923,37.84307692307692,38.005384615384614,38.167692307692306,{"y":38.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.22,35.433846153846154,34.64769230769231,33.86153846153846,33.075384615384614,32.28923076923077,31.50307692307692,30.716923076923077,29.93076923076923,29.144615384615385,28.358461538461537,27.572307692307692,26.786153846153844,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.7,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":45.67,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.23,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":37.68,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.85,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.86,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.3,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.52,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":38.23,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":39.71,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.22,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€50.00Average Price Target€38.33Lowest Price Target€26.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
€41€40
Hold
9.08%
Upside
Reiterated
02/27/24
Morgan Stanley
€33€34
Sell
-7.28%
Downside
Reiterated
02/23/24
Fresenius Medical Care AG #x26; Co KGaA (FME:GR) (FMS) PT Raised to EUR34 at Morgan StanleyMorgan Stanley analyst Robert Davies raised the price target on Fresenius Medical Care AG Co KGaA (FME:GR) (NYSE: FMS) to EUR34.00 (from EUR33.00) while maintaining a Underweight rating.
HSBC
€38€39
Hold
6.35%
Upside
Upgraded
11/24/23
Fresenius Medical upgraded to Hold from Reduce at HSBCFresenius Medical upgraded to Hold from Reduce at HSBC
Credit Suisse
€42€45
Hold
22.72%
Upside
Reiterated
08/07/23
Citi
€52
Hold
41.81%
Upside
Initiated
08/01/23
Fresenius Medical resumed with a Neutral at CitiFresenius Medical resumed with a Neutral at Citi

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

Which Analyst Should I Follow If I Want to Buy GB:0H9X and Sell After:
1 Month
David AdlingtonJ.P. Morgan
Success Rate
21/45 ratings generated profit
47%
Average Return
-1.26%
reiterated a sell rating 2 months ago
Copying David Adlington's trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of -1.26% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
David AdlingtonJ.P. Morgan
Success Rate
21/45 ratings generated profit
47%
Average Return
+1.15%
reiterated a sell rating 2 months ago
Copying David Adlington's trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +1.15% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
James VaneJefferies
Success Rate
20/32 ratings generated profit
63%
Average Return
+1.54%
reiterated a sell rating 29 days ago
Copying James Vane's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +1.54% per trade.
2 Years
James VaneJefferies
Success Rate
20/32 ratings generated profit
63%
Average Return
+1.66%
reiterated a sell rating 29 days ago
Copying James Vane's trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +1.66% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0H9X Analyst Recommendation Trends

Rating
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Strong Buy
0
0
0
0
0
Buy
5
5
7
7
6
Hold
16
14
12
9
6
Sell
11
13
13
14
8
Strong Sell
2
1
0
0
0
total
34
33
32
30
20
In the current month, 0H9X has received 6 Buy Ratings, 6 Hold Ratings, and 8 Sell Ratings. 0H9X average Analyst price target in the past 3 months is €38.33.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0H9X Financial Forecast

0H9X Earnings Forecast

Next quarter’s earnings estimate for 0H9X is €0.68 with a range of €0.59 to €0.75. The previous quarter’s EPS was €0.67. 0H9X beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.00% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.
Next quarter’s earnings estimate for 0H9X is €0.68 with a range of €0.59 to €0.75. The previous quarter’s EPS was €0.67. 0H9X beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.00% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.

0H9X Sales Forecast

Next quarter’s sales forecast for 0H9X is €5.02B with a range of €4.73B to €5.80B. The previous quarter’s sales results were €4.72B. 0H9X beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 44.16% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.
Next quarter’s sales forecast for 0H9X is €5.02B with a range of €4.73B to €5.80B. The previous quarter’s sales results were €4.72B. 0H9X beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 44.16% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.

0H9X Stock Forecast FAQ

What is GB:0H9X’s average 12-month price target, according to analysts?
Based on analyst ratings, Fresenius Medical Care AG & Co. KGaA’s 12-month average price target is €38.33.
    What is GB:0H9X’s upside potential, based on the analysts’ average price target?
    Fresenius Medical Care AG & Co. KGaA has 4.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Fresenius Medical Care AG & Co. KGaA a Buy, Sell or Hold?
          Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold, which is based on 2 buy ratings, 5 hold ratings and 4 sell ratings.
            What is Fresenius Medical Care AG & Co. KGaA’s share price target?
            The average share price target for Fresenius Medical Care AG & Co. KGaA is €38.33. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €50.00 ,and the lowest forecast is €26.00. The average share price target represents 4.53% Increase from the current price of €36.67.
              What do analysts say about Fresenius Medical Care AG & Co. KGaA?
              Fresenius Medical Care AG & Co. KGaA’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Fresenius Medical Care AG & Co. KGaA?
                To buy shares of GB:0H9X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis